{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:25:41Z","timestamp":1757705141014},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1997,12,1]]},"DOI":"10.1093\/ajhp\/54.23.2689","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T20:49:44Z","timestamp":1550782184000},"page":"2689-2703","source":"Crossref","is-referenced-by-count":18,"title":["Oral angiotensin-converting-enzyme inhibitors"],"prefix":"10.1093","volume":"54","author":[{"given":"Catherine","family":"Verme-Gibboney","sequence":"first","affiliation":[{"name":"SmithKline Beecham Pharmaceuticals, Philadelphia, PA; when this monograph was written she was at the University of Cincinnati Hospital, Cincinnati, OH."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/54\/23\/2689\/28396432\/ajhp2689.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T13:40:00Z","timestamp":1555162800000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/54\/23\/2689\/5158378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,12,1]]},"references-count":0,"journal-issue":{"issue":"23","published-print":{"date-parts":[[1997,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/54.23.2689","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[1997,12,1]]},"published":{"date-parts":[[1997,12,1]]}}}